nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—melanoma—kidney cancer	0.619	1	CtDrD
Temozolomide—CYP3A4—Everolimus—kidney cancer	0.062	0.293	CbGbCtD
Temozolomide—CYP3A4—Temsirolimus—kidney cancer	0.0419	0.198	CbGbCtD
Temozolomide—CYP3A4—Pazopanib—kidney cancer	0.022	0.104	CbGbCtD
Temozolomide—CYP3A4—Erlotinib—kidney cancer	0.0157	0.0741	CbGbCtD
Temozolomide—CYP3A4—Paclitaxel—kidney cancer	0.0144	0.0678	CbGbCtD
Temozolomide—CYP3A4—Sorafenib—kidney cancer	0.0128	0.0603	CbGbCtD
Temozolomide—CYP3A4—Vinblastine—kidney cancer	0.0126	0.0595	CbGbCtD
Temozolomide—CYP3A4—Vincristine—kidney cancer	0.0124	0.0585	CbGbCtD
Temozolomide—CYP3A4—Sunitinib—kidney cancer	0.0103	0.0488	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—kidney cancer	0.00775	0.0366	CbGbCtD
Temozolomide—Face oedema—Doxorubicin—kidney cancer	5e-05	0.000295	CcSEcCtD
Temozolomide—Decreased appetite—Gemcitabine—kidney cancer	5e-05	0.000295	CcSEcCtD
Temozolomide—Hypersensitivity—Dactinomycin—kidney cancer	5e-05	0.000295	CcSEcCtD
Temozolomide—Chills—Capecitabine—kidney cancer	4.99e-05	0.000294	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	4.98e-05	0.000294	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.96e-05	0.000293	CcSEcCtD
Temozolomide—Discomfort—Paclitaxel—kidney cancer	4.96e-05	0.000293	CcSEcCtD
Temozolomide—Fatigue—Gemcitabine—kidney cancer	4.95e-05	0.000293	CcSEcCtD
Temozolomide—Gastrointestinal pain—Vincristine—kidney cancer	4.95e-05	0.000292	CcSEcCtD
Temozolomide—Dizziness—Sorafenib—kidney cancer	4.92e-05	0.000291	CcSEcCtD
Temozolomide—Pain—Gemcitabine—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Constipation—Gemcitabine—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Nausea—Erlotinib—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Alopecia—Capecitabine—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Dry mouth—Paclitaxel—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Mood swings—Doxorubicin—kidney cancer	4.91e-05	0.00029	CcSEcCtD
Temozolomide—Diarrhoea—Sunitinib—kidney cancer	4.9e-05	0.000289	CcSEcCtD
Temozolomide—Ataxia—Doxorubicin—kidney cancer	4.87e-05	0.000288	CcSEcCtD
Temozolomide—Mental disorder—Capecitabine—kidney cancer	4.87e-05	0.000288	CcSEcCtD
Temozolomide—Asthenia—Dactinomycin—kidney cancer	4.86e-05	0.000287	CcSEcCtD
Temozolomide—Confusional state—Paclitaxel—kidney cancer	4.85e-05	0.000286	CcSEcCtD
Temozolomide—Malnutrition—Capecitabine—kidney cancer	4.84e-05	0.000286	CcSEcCtD
Temozolomide—Erythema—Capecitabine—kidney cancer	4.84e-05	0.000286	CcSEcCtD
Temozolomide—Dehydration—Doxorubicin—kidney cancer	4.82e-05	0.000284	CcSEcCtD
Temozolomide—Oedema—Paclitaxel—kidney cancer	4.81e-05	0.000284	CcSEcCtD
Temozolomide—Anaphylactic shock—Paclitaxel—kidney cancer	4.81e-05	0.000284	CcSEcCtD
Temozolomide—Abdominal pain—Vincristine—kidney cancer	4.79e-05	0.000283	CcSEcCtD
Temozolomide—Body temperature increased—Vincristine—kidney cancer	4.79e-05	0.000283	CcSEcCtD
Temozolomide—Infection—Paclitaxel—kidney cancer	4.78e-05	0.000282	CcSEcCtD
Temozolomide—Dry skin—Doxorubicin—kidney cancer	4.75e-05	0.00028	CcSEcCtD
Temozolomide—Dysgeusia—Capecitabine—kidney cancer	4.74e-05	0.00028	CcSEcCtD
Temozolomide—Dizziness—Sunitinib—kidney cancer	4.74e-05	0.00028	CcSEcCtD
Temozolomide—Feeling abnormal—Gemcitabine—kidney cancer	4.74e-05	0.00028	CcSEcCtD
Temozolomide—Vomiting—Sorafenib—kidney cancer	4.73e-05	0.000279	CcSEcCtD
Temozolomide—Nervous system disorder—Paclitaxel—kidney cancer	4.72e-05	0.000279	CcSEcCtD
Temozolomide—Hypokalaemia—Doxorubicin—kidney cancer	4.71e-05	0.000278	CcSEcCtD
Temozolomide—Thrombocytopenia—Paclitaxel—kidney cancer	4.71e-05	0.000278	CcSEcCtD
Temozolomide—Rash—Sorafenib—kidney cancer	4.69e-05	0.000277	CcSEcCtD
Temozolomide—Dermatitis—Sorafenib—kidney cancer	4.69e-05	0.000277	CcSEcCtD
Temozolomide—Back pain—Capecitabine—kidney cancer	4.68e-05	0.000276	CcSEcCtD
Temozolomide—Breast disorder—Doxorubicin—kidney cancer	4.68e-05	0.000276	CcSEcCtD
Temozolomide—Skin disorder—Paclitaxel—kidney cancer	4.67e-05	0.000276	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.66e-05	0.000275	CcSEcCtD
Temozolomide—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	4.66e-05	0.000275	CcSEcCtD
Temozolomide—Headache—Sorafenib—kidney cancer	4.66e-05	0.000275	CcSEcCtD
Temozolomide—Hyperhidrosis—Paclitaxel—kidney cancer	4.65e-05	0.000275	CcSEcCtD
Temozolomide—Diarrhoea—Dactinomycin—kidney cancer	4.64e-05	0.000274	CcSEcCtD
Temozolomide—Anorexia—Paclitaxel—kidney cancer	4.59e-05	0.000271	CcSEcCtD
Temozolomide—Muscular weakness—Doxorubicin—kidney cancer	4.57e-05	0.00027	CcSEcCtD
Temozolomide—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.57e-05	0.00027	CcSEcCtD
Temozolomide—Vision blurred—Capecitabine—kidney cancer	4.56e-05	0.000269	CcSEcCtD
Temozolomide—Vomiting—Sunitinib—kidney cancer	4.55e-05	0.000269	CcSEcCtD
Temozolomide—Body temperature increased—Gemcitabine—kidney cancer	4.54e-05	0.000268	CcSEcCtD
Temozolomide—Tremor—Capecitabine—kidney cancer	4.53e-05	0.000268	CcSEcCtD
Temozolomide—Rash—Sunitinib—kidney cancer	4.52e-05	0.000267	CcSEcCtD
Temozolomide—Dermatitis—Sunitinib—kidney cancer	4.51e-05	0.000266	CcSEcCtD
Temozolomide—Abdominal distension—Doxorubicin—kidney cancer	4.51e-05	0.000266	CcSEcCtD
Temozolomide—Ill-defined disorder—Capecitabine—kidney cancer	4.49e-05	0.000265	CcSEcCtD
Temozolomide—Headache—Sunitinib—kidney cancer	4.49e-05	0.000265	CcSEcCtD
Temozolomide—Dysphagia—Doxorubicin—kidney cancer	4.48e-05	0.000264	CcSEcCtD
Temozolomide—Anaemia—Capecitabine—kidney cancer	4.47e-05	0.000264	CcSEcCtD
Temozolomide—Hypersensitivity—Vincristine—kidney cancer	4.46e-05	0.000264	CcSEcCtD
Temozolomide—Nausea—Sorafenib—kidney cancer	4.42e-05	0.000261	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.38e-05	0.000259	CcSEcCtD
Temozolomide—Malaise—Capecitabine—kidney cancer	4.36e-05	0.000258	CcSEcCtD
Temozolomide—Insomnia—Paclitaxel—kidney cancer	4.35e-05	0.000257	CcSEcCtD
Temozolomide—Vertigo—Capecitabine—kidney cancer	4.35e-05	0.000257	CcSEcCtD
Temozolomide—Asthenia—Vincristine—kidney cancer	4.35e-05	0.000257	CcSEcCtD
Temozolomide—Leukopenia—Capecitabine—kidney cancer	4.33e-05	0.000256	CcSEcCtD
Temozolomide—Paraesthesia—Paclitaxel—kidney cancer	4.32e-05	0.000255	CcSEcCtD
Temozolomide—Vomiting—Dactinomycin—kidney cancer	4.31e-05	0.000255	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—kidney cancer	4.3e-05	0.000254	CcSEcCtD
Temozolomide—Dyspnoea—Paclitaxel—kidney cancer	4.29e-05	0.000253	CcSEcCtD
Temozolomide—Somnolence—Paclitaxel—kidney cancer	4.28e-05	0.000253	CcSEcCtD
Temozolomide—Palpitations—Capecitabine—kidney cancer	4.28e-05	0.000252	CcSEcCtD
Temozolomide—Rash—Dactinomycin—kidney cancer	4.28e-05	0.000252	CcSEcCtD
Temozolomide—Nausea—Sunitinib—kidney cancer	4.25e-05	0.000251	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—kidney cancer	4.25e-05	0.000251	CcSEcCtD
Temozolomide—Dyspepsia—Paclitaxel—kidney cancer	4.24e-05	0.00025	CcSEcCtD
Temozolomide—Cough—Capecitabine—kidney cancer	4.22e-05	0.000249	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—kidney cancer	4.19e-05	0.000247	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—kidney cancer	4.19e-05	0.000247	CcSEcCtD
Temozolomide—Decreased appetite—Paclitaxel—kidney cancer	4.18e-05	0.000247	CcSEcCtD
Temozolomide—Hypertension—Capecitabine—kidney cancer	4.18e-05	0.000247	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—kidney cancer	4.16e-05	0.000246	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.15e-05	0.000245	CcSEcCtD
Temozolomide—Fatigue—Paclitaxel—kidney cancer	4.15e-05	0.000245	CcSEcCtD
Temozolomide—Diarrhoea—Vincristine—kidney cancer	4.14e-05	0.000245	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—kidney cancer	4.13e-05	0.000244	CcSEcCtD
Temozolomide—Asthenia—Gemcitabine—kidney cancer	4.12e-05	0.000243	CcSEcCtD
Temozolomide—Arthralgia—Capecitabine—kidney cancer	4.12e-05	0.000243	CcSEcCtD
Temozolomide—Myalgia—Capecitabine—kidney cancer	4.12e-05	0.000243	CcSEcCtD
Temozolomide—Constipation—Paclitaxel—kidney cancer	4.11e-05	0.000243	CcSEcCtD
Temozolomide—Pain—Paclitaxel—kidney cancer	4.11e-05	0.000243	CcSEcCtD
Temozolomide—Anxiety—Capecitabine—kidney cancer	4.1e-05	0.000242	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.09e-05	0.000242	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—kidney cancer	4.09e-05	0.000241	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—kidney cancer	4.07e-05	0.000241	CcSEcCtD
Temozolomide—Discomfort—Capecitabine—kidney cancer	4.07e-05	0.00024	CcSEcCtD
Temozolomide—Pruritus—Gemcitabine—kidney cancer	4.07e-05	0.00024	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—kidney cancer	4.05e-05	0.000239	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—kidney cancer	4.04e-05	0.000238	CcSEcCtD
Temozolomide—Dry mouth—Capecitabine—kidney cancer	4.03e-05	0.000238	CcSEcCtD
Temozolomide—Nausea—Dactinomycin—kidney cancer	4.03e-05	0.000238	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—kidney cancer	4.01e-05	0.000237	CcSEcCtD
Temozolomide—Dizziness—Vincristine—kidney cancer	4.01e-05	0.000237	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—kidney cancer	3.99e-05	0.000236	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—kidney cancer	3.99e-05	0.000236	CcSEcCtD
Temozolomide—Confusional state—Capecitabine—kidney cancer	3.98e-05	0.000235	CcSEcCtD
Temozolomide—Feeling abnormal—Paclitaxel—kidney cancer	3.96e-05	0.000234	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.96e-05	0.000234	CcSEcCtD
Temozolomide—Oedema—Capecitabine—kidney cancer	3.95e-05	0.000233	CcSEcCtD
Temozolomide—Gastrointestinal pain—Paclitaxel—kidney cancer	3.93e-05	0.000232	CcSEcCtD
Temozolomide—Diarrhoea—Gemcitabine—kidney cancer	3.93e-05	0.000232	CcSEcCtD
Temozolomide—Infection—Capecitabine—kidney cancer	3.92e-05	0.000232	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—kidney cancer	3.91e-05	0.000231	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—kidney cancer	3.89e-05	0.00023	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—kidney cancer	3.88e-05	0.000229	CcSEcCtD
Temozolomide—Nervous system disorder—Capecitabine—kidney cancer	3.87e-05	0.000229	CcSEcCtD
Temozolomide—Thrombocytopenia—Capecitabine—kidney cancer	3.87e-05	0.000228	CcSEcCtD
Temozolomide—Vomiting—Vincristine—kidney cancer	3.85e-05	0.000227	CcSEcCtD
Temozolomide—Skin disorder—Capecitabine—kidney cancer	3.84e-05	0.000226	CcSEcCtD
Temozolomide—Urticaria—Paclitaxel—kidney cancer	3.82e-05	0.000226	CcSEcCtD
Temozolomide—Rash—Vincristine—kidney cancer	3.82e-05	0.000226	CcSEcCtD
Temozolomide—Hyperhidrosis—Capecitabine—kidney cancer	3.82e-05	0.000225	CcSEcCtD
Temozolomide—Dermatitis—Vincristine—kidney cancer	3.82e-05	0.000225	CcSEcCtD
Temozolomide—Abdominal pain—Paclitaxel—kidney cancer	3.8e-05	0.000225	CcSEcCtD
Temozolomide—Body temperature increased—Paclitaxel—kidney cancer	3.8e-05	0.000225	CcSEcCtD
Temozolomide—Headache—Vincristine—kidney cancer	3.8e-05	0.000224	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—kidney cancer	3.77e-05	0.000223	CcSEcCtD
Temozolomide—Anorexia—Capecitabine—kidney cancer	3.76e-05	0.000222	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—kidney cancer	3.74e-05	0.000221	CcSEcCtD
Temozolomide—Vomiting—Gemcitabine—kidney cancer	3.65e-05	0.000216	CcSEcCtD
Temozolomide—Rash—Gemcitabine—kidney cancer	3.62e-05	0.000214	CcSEcCtD
Temozolomide—Dermatitis—Gemcitabine—kidney cancer	3.62e-05	0.000214	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—kidney cancer	3.6e-05	0.000213	CcSEcCtD
Temozolomide—Headache—Gemcitabine—kidney cancer	3.6e-05	0.000213	CcSEcCtD
Temozolomide—Nausea—Vincristine—kidney cancer	3.6e-05	0.000212	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.6e-05	0.000212	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—kidney cancer	3.58e-05	0.000212	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—kidney cancer	3.58e-05	0.000212	CcSEcCtD
Temozolomide—Insomnia—Capecitabine—kidney cancer	3.57e-05	0.000211	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—kidney cancer	3.56e-05	0.00021	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—kidney cancer	3.56e-05	0.00021	CcSEcCtD
Temozolomide—Paraesthesia—Capecitabine—kidney cancer	3.55e-05	0.000209	CcSEcCtD
Temozolomide—Hypersensitivity—Paclitaxel—kidney cancer	3.54e-05	0.000209	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—kidney cancer	3.54e-05	0.000209	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—kidney cancer	3.53e-05	0.000208	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—kidney cancer	3.52e-05	0.000208	CcSEcCtD
Temozolomide—Dyspnoea—Capecitabine—kidney cancer	3.52e-05	0.000208	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—kidney cancer	3.51e-05	0.000207	CcSEcCtD
Temozolomide—Dyspepsia—Capecitabine—kidney cancer	3.48e-05	0.000205	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—kidney cancer	3.45e-05	0.000204	CcSEcCtD
Temozolomide—Asthenia—Paclitaxel—kidney cancer	3.45e-05	0.000204	CcSEcCtD
Temozolomide—Decreased appetite—Capecitabine—kidney cancer	3.43e-05	0.000203	CcSEcCtD
Temozolomide—Nausea—Gemcitabine—kidney cancer	3.41e-05	0.000202	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Capecitabine—kidney cancer	3.41e-05	0.000201	CcSEcCtD
Temozolomide—Fatigue—Capecitabine—kidney cancer	3.4e-05	0.000201	CcSEcCtD
Temozolomide—Pruritus—Paclitaxel—kidney cancer	3.4e-05	0.000201	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—kidney cancer	3.39e-05	0.0002	CcSEcCtD
Temozolomide—Pain—Capecitabine—kidney cancer	3.38e-05	0.000199	CcSEcCtD
Temozolomide—Constipation—Capecitabine—kidney cancer	3.38e-05	0.000199	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—kidney cancer	3.35e-05	0.000198	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—kidney cancer	3.34e-05	0.000197	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—kidney cancer	3.32e-05	0.000196	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—kidney cancer	3.32e-05	0.000196	CcSEcCtD
Temozolomide—Diarrhoea—Paclitaxel—kidney cancer	3.29e-05	0.000194	CcSEcCtD
Temozolomide—Feeling abnormal—Capecitabine—kidney cancer	3.25e-05	0.000192	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—kidney cancer	3.25e-05	0.000192	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—kidney cancer	3.24e-05	0.000191	CcSEcCtD
Temozolomide—Gastrointestinal pain—Capecitabine—kidney cancer	3.23e-05	0.000191	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—kidney cancer	3.23e-05	0.000191	CcSEcCtD
Temozolomide—Chills—Doxorubicin—kidney cancer	3.21e-05	0.00019	CcSEcCtD
Temozolomide—Dizziness—Paclitaxel—kidney cancer	3.18e-05	0.000188	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—kidney cancer	3.17e-05	0.000187	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—kidney cancer	3.14e-05	0.000185	CcSEcCtD
Temozolomide—Urticaria—Capecitabine—kidney cancer	3.14e-05	0.000185	CcSEcCtD
Temozolomide—Abdominal pain—Capecitabine—kidney cancer	3.12e-05	0.000184	CcSEcCtD
Temozolomide—Body temperature increased—Capecitabine—kidney cancer	3.12e-05	0.000184	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—kidney cancer	3.12e-05	0.000184	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—kidney cancer	3.12e-05	0.000184	CcSEcCtD
Temozolomide—Vomiting—Paclitaxel—kidney cancer	3.06e-05	0.000181	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—kidney cancer	3.05e-05	0.00018	CcSEcCtD
Temozolomide—Rash—Paclitaxel—kidney cancer	3.03e-05	0.000179	CcSEcCtD
Temozolomide—Dermatitis—Paclitaxel—kidney cancer	3.03e-05	0.000179	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—kidney cancer	3.02e-05	0.000178	CcSEcCtD
Temozolomide—Headache—Paclitaxel—kidney cancer	3.01e-05	0.000178	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—kidney cancer	2.94e-05	0.000174	CcSEcCtD
Temozolomide—Hypersensitivity—Capecitabine—kidney cancer	2.91e-05	0.000172	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—kidney cancer	2.89e-05	0.000171	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—kidney cancer	2.88e-05	0.00017	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—kidney cancer	2.87e-05	0.000169	CcSEcCtD
Temozolomide—Nausea—Paclitaxel—kidney cancer	2.86e-05	0.000169	CcSEcCtD
Temozolomide—Asthenia—Capecitabine—kidney cancer	2.83e-05	0.000167	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—kidney cancer	2.81e-05	0.000166	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—kidney cancer	2.8e-05	0.000165	CcSEcCtD
Temozolomide—Pruritus—Capecitabine—kidney cancer	2.79e-05	0.000165	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—kidney cancer	2.79e-05	0.000165	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—kidney cancer	2.76e-05	0.000163	CcSEcCtD
Temozolomide—Cough—Doxorubicin—kidney cancer	2.72e-05	0.000161	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—kidney cancer	2.7e-05	0.00016	CcSEcCtD
Temozolomide—Diarrhoea—Capecitabine—kidney cancer	2.7e-05	0.00016	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—kidney cancer	2.69e-05	0.000159	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—kidney cancer	2.66e-05	0.000157	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—kidney cancer	2.66e-05	0.000157	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—kidney cancer	2.65e-05	0.000156	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.64e-05	0.000156	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—kidney cancer	2.62e-05	0.000155	CcSEcCtD
Temozolomide—Dizziness—Capecitabine—kidney cancer	2.61e-05	0.000154	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—kidney cancer	2.6e-05	0.000153	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—kidney cancer	2.57e-05	0.000152	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—kidney cancer	2.55e-05	0.00015	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—kidney cancer	2.55e-05	0.00015	CcSEcCtD
Temozolomide—Infection—Doxorubicin—kidney cancer	2.53e-05	0.000149	CcSEcCtD
Temozolomide—Vomiting—Capecitabine—kidney cancer	2.51e-05	0.000148	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—kidney cancer	2.5e-05	0.000147	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—kidney cancer	2.49e-05	0.000147	CcSEcCtD
Temozolomide—Rash—Capecitabine—kidney cancer	2.49e-05	0.000147	CcSEcCtD
Temozolomide—Dermatitis—Capecitabine—kidney cancer	2.49e-05	0.000147	CcSEcCtD
Temozolomide—Headache—Capecitabine—kidney cancer	2.47e-05	0.000146	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—kidney cancer	2.47e-05	0.000146	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—kidney cancer	2.46e-05	0.000145	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—kidney cancer	2.43e-05	0.000143	CcSEcCtD
Temozolomide—Nausea—Capecitabine—kidney cancer	2.35e-05	0.000138	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.32e-05	0.000137	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—kidney cancer	2.3e-05	0.000136	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—kidney cancer	2.29e-05	0.000135	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—kidney cancer	2.27e-05	0.000134	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—kidney cancer	2.26e-05	0.000134	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—kidney cancer	2.24e-05	0.000132	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—kidney cancer	2.21e-05	0.000131	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.2e-05	0.00013	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—kidney cancer	2.19e-05	0.00013	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—kidney cancer	2.18e-05	0.000129	CcSEcCtD
Temozolomide—Pain—Doxorubicin—kidney cancer	2.18e-05	0.000129	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—kidney cancer	2.1e-05	0.000124	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—kidney cancer	2.08e-05	0.000123	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—kidney cancer	2.02e-05	0.000119	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—kidney cancer	2.01e-05	0.000119	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—kidney cancer	2.01e-05	0.000119	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—kidney cancer	1.88e-05	0.000111	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—kidney cancer	1.83e-05	0.000108	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—kidney cancer	1.8e-05	0.000106	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—kidney cancer	1.74e-05	0.000103	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—kidney cancer	1.68e-05	9.94e-05	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—kidney cancer	1.62e-05	9.56e-05	CcSEcCtD
Temozolomide—Rash—Doxorubicin—kidney cancer	1.6e-05	9.48e-05	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—kidney cancer	1.6e-05	9.47e-05	CcSEcCtD
Temozolomide—Headache—Doxorubicin—kidney cancer	1.59e-05	9.41e-05	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—kidney cancer	1.51e-05	8.93e-05	CcSEcCtD
